These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 1548516)
1. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. Jodrell DI; Egorin MJ; Canetta RM; Langenberg P; Goldbloom EP; Burroughs JN; Goodlow JL; Tan S; Wiltshaw E J Clin Oncol; 1992 Apr; 10(4):520-8. PubMed ID: 1548516 [TBL] [Abstract][Full Text] [Related]
2. Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. Reyno LM; Egorin MJ; Canetta RM; Jodrell DI; Swenerton KD; Pater JL; Burroughs JN; Novak MJ; Sridhara R J Clin Oncol; 1993 Jun; 11(6):1156-64. PubMed ID: 8501502 [TBL] [Abstract][Full Text] [Related]
4. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer. Meerpohl HG; du Bois A; Kühnle H; Lück HJ; Kreienberg R; Möbus V; Bauknecht T; Köchli O; Bochtler H; Diergarten K Semin Oncol; 1995 Dec; 22(6 Suppl 15):7-12. PubMed ID: 8643973 [TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics and dose optimisation of carboplatin. Duffull SB; Robinson BA Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610 [TBL] [Abstract][Full Text] [Related]
6. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date. Harper P Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217 [TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. Huizing MT; van Warmerdam LJ; Rosing H; Schaefers MC; Lai A; Helmerhorst TJ; Veenhof CH; Birkhofer MJ; Rodenhuis S; Beijnen JH; ten Bokkel Huinink WW J Clin Oncol; 1997 May; 15(5):1953-64. PubMed ID: 9164207 [TBL] [Abstract][Full Text] [Related]
8. [Evaluation of expected AUC of carboplatin (CBDCA) predicted by Chatelut's formula in comparison with Calvert's]. Nakamura T; Onishi Y; Kono T; Maeda T; Wada T; Hatae M Gan To Kagaku Ryoho; 1997 Mar; 24(5):579-83. PubMed ID: 9087291 [TBL] [Abstract][Full Text] [Related]
9. A phase II study of intraperitoneal carboplatin as adjuvant treatment in early-stage ovarian cancer patients. Malmström H; Simonsen E; Westberg R Gynecol Oncol; 1994 Jan; 52(1):20-5. PubMed ID: 8307496 [TBL] [Abstract][Full Text] [Related]
10. Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients. Chambers SK; Davis CA; Chambers JT; Schwartz PE; Lorber MI; Hschumacher RE Clin Cancer Res; 1996 Oct; 2(10):1699-704. PubMed ID: 9816119 [TBL] [Abstract][Full Text] [Related]
11. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer. Lund B; Hansen OP; Hansen HH; Hansen M Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618 [TBL] [Abstract][Full Text] [Related]
12. Carboplatin-based combination chemotherapy for testicular cancer: relationship among administration dose of carboplatin, renal function and myelosuppression. Suzuki K; Matsumoto K; Hashimoto K; Kurokawa K; Jinbo S; Suzuki T; Imai K; Yamanaka H; Kawashima K; Takahashi H Hinyokika Kiyo; 1995 Oct; 41(10):775-80. PubMed ID: 8533673 [TBL] [Abstract][Full Text] [Related]
13. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group. Newell DR; Pearson AD; Balmanno K; Price L; Wyllie RA; Keir M; Calvert AH; Lewis IJ; Pinkerton CR; Stevens MC J Clin Oncol; 1993 Dec; 11(12):2314-23. PubMed ID: 8246021 [TBL] [Abstract][Full Text] [Related]
14. [Dose finding study of paclitaxel and carboplatin for ovarian cancer (JKTB)]. Yasuda M; Kimura E; Ochiai K; Tada S; Udagawa Y; Aoki D; Nozawa S; Kikuchi Y; Kita T; Nishida M; Tsunoda H Gan To Kagaku Ryoho; 2001 Apr; 28(4):493-8. PubMed ID: 11329783 [TBL] [Abstract][Full Text] [Related]
15. Prediction of hematologic toxicity of carboplatin by creatinine clearance rate. Taguchi J; Saijo N; Miura K; Shinkai T; Eguchi K; Sasaki Y; Tamura T; Sakurai M; Minato K; Fujiwara Y Jpn J Cancer Res; 1987 Sep; 78(9):977-82. PubMed ID: 3117753 [TBL] [Abstract][Full Text] [Related]
16. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Ozols RF J Clin Oncol; 1995 Aug; 13(8):1860-70. PubMed ID: 7543559 [TBL] [Abstract][Full Text] [Related]
17. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer. Adachi S; Ogasawara T; Ito K; Koyama M; Nagano T; Suzuki A; Yamada T; Nakata Y; Ozawa M Oncol Rep; 2001; 8(2):285-8. PubMed ID: 11182041 [TBL] [Abstract][Full Text] [Related]
20. Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study. Chambers SK; Davis CA; Schwartz PE; Kohorn EI; Chambers JT Clin Cancer Res; 1996 Oct; 2(10):1693-7. PubMed ID: 9816118 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]